Adbry 300 mg/2mL
tralokinumab-ldrm · INJECTION, SOLUTION · LEO Pharma Inc.
No Recall History
Plain English
Adbry is a injection, solution containing tralokinumab-ldrm at 300 mg/2mL, taken subcutaneous. Manufactured by LEO Pharma Inc..
Key Facts
- Brand Name
- Adbry
- Generic Name
- tralokinumab-ldrm
- NDC Code (Product)
50222-350- Manufacturer
- LEO Pharma Inc.
- Strength
- 300 mg/2mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761180
- Drug Class
- Interleukin-13 Antagonist [EPC]
- Marketing Start
- 07/01/2024
Recall History
No Recall HistoryFrequently Asked Questions
What is Adbry used for?
Adbry contains tralokinumab-ldrm. It is a injection, solution taken subcutaneous. Consult your doctor for specific uses.
Is Adbry a controlled substance?
Adbry is not classified as a controlled substance by the DEA.
What is the generic name for Adbry?
The generic name for Adbry is tralokinumab-ldrm. There are no other listed brand versions of tralokinumab-ldrm.
What is the NDC code for Adbry 300 mg/2mL?
The NDC (National Drug Code) for Adbry 300 mg/2mL is 50222-350, listed by LEO Pharma Inc..
Other Adbry Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)